Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Gross Profit (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Gross Profit for 6 consecutive years, with $7.5 million as the latest value for Q1 2018.

  • On a quarterly basis, Gross Profit rose 197.11% to $7.5 million in Q1 2018 year-over-year; TTM through Mar 2018 was $14.3 million, a 576.93% increase, with the full-year FY2017 number at $9.4 million, down 22.72% from a year prior.
  • Gross Profit was $7.5 million for Q1 2018 at Theravance Biopharma, up from $1.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $20.0 million in Q1 2015 to a low of -$29.1 million in Q4 2016.
  • A 5-year average of $2.8 million and a median of $3.3 million in 2017 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: skyrocketed 53800.0% in 2014, then plummeted 1377.53% in 2015.
  • Theravance Biopharma's Gross Profit stood at -$1.8 million in 2014, then tumbled by 1377.53% to -$26.4 million in 2015, then decreased by 10.1% to -$29.1 million in 2016, then skyrocketed by 104.81% to $1.4 million in 2017, then soared by 435.6% to $7.5 million in 2018.
  • Per Business Quant, the three most recent readings for TBPH's Gross Profit are $7.5 million (Q1 2018), $1.4 million (Q4 2017), and $3.3 million (Q3 2017).